Originally published October 11 2004
Rheumatoid arthritis drug Remicade raises risk of cancer, admits Johnson & Johnson
by Mike Adams, the Health Ranger, NaturalNews Editor
And yet, the FDA won't be banning the drug any time soon. Sure, it causes cancer, but it still generates revenues that are great for the pharmaceutical industry.
-
Johnson & Johnson will send a letter to doctors next Monday warning them that patients taking its rheumatoid arthritis drug Remicade may have a higher risk of lymphoma, a blood cancer, than those not taking the drug, the company said on Friday.
- The warning, which will be added to the drug's package insert, means the drug's safety profile will more closely match that of rival drugs in the same class, Amgen Inc.'s Enbrel and Abbott Laboratories Inc.'s Humira.
- The label will warn of a three-fold increase in the risk for rheumatoid arthritis patients taking the drug compared with the normal population, according to J&J's Centocor unit.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml